Challenges and Innovation for Diagnosing and Treatment of Secondary Progressive Multiple Sclerosis
International Journal of Molecular Sciences · 19.05.2026 · 27 (10) · 4558
DOI: 10.3390/ijms27104558 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 19.05.2026. Verfasst von Ekdanai Uawithya und 5 weiteren Autor:innen. Beteiligte Einrichtung: Arthritis and Clinical Immunology Program, Oklahoma Medical Research Foundation, 825 NE 13th Street, Oklahoma City, OK 73104, USA. Hauptthemen laut MEDLINE: Multiple Sclerosis, Chronic Progressive, Multiple Sclerosis, Relapsing-Remitting. Die Arbeit nennt 197 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
The transition from relapsing–remitting multiple sclerosis (RRMS) to secondary-progressive multiple sclerosis (SPMS) represents an ambiguous transition period characterized by diagnostic delays and a shifting therapeutic window. While inflammatory relapses are well-managed, the underlying neurodegeneration often remains undetected until substantial disability has accrued. This review evaluated the shift from traditional metrics, such as the Expanded Disability Status Scale (EDSS), toward more sensitive, multimodal monitoring strategies. We described characteristic MRI findings in SPMS and addressed the impact of comorbidities that frequently confound the diagnosis of disease transition. Furthermore, we evaluated the predictive potential of emerging fluid biomarkers and gut microbial signatures in identifying the early RRMS-to-SPMS transition. Finally, we described the current therapeutic landscape and emerging immunomodulatory interventions. Diagnosing SPMS remains a clinical challenge due to comorbidities and the lack of a singular definitive marker. Moving toward high-sensitivity imaging and molecular biomarkers is essential for the early initiation of treatments and improved patient outcomes.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Arthritis and Clinical Immunology Program, Oklahoma Medical Research Foundation, 825 NE 13th Street, Oklahoma City, OK 73104, USA.
ORCID-Profile: Ekdanai Uawithya, Joshua S Mytych, Ismail Muwenda
Zitieren
APA
Uawithya, E., Mytych, J. S., Muwenda, I., Reidy, M., Khan, M., & Mao-Draayer, Y. (2026). Challenges and Innovation for Diagnosing and Treatment of Secondary Progressive Multiple Sclerosis. International Journal of Molecular Sciences, 27(10), 4558. https://doi.org/10.3390/ijms27104558
Vancouver
Uawithya E, Mytych JS, Muwenda I, Reidy M, Khan M, Mao-Draayer Y. Challenges and Innovation for Diagnosing and Treatment of Secondary Progressive Multiple Sclerosis. International Journal of Molecular Sciences. 2026;27(10):4558. doi:10.3390/ijms27104558
BibTeX
@article{Uawithya2026,
author = {Uawithya, Ekdanai and Mytych, Joshua S and Muwenda, Ismail and Reidy, Megan and Khan, Meerah and Mao-Draayer, Yang},
title = {Challenges and Innovation for Diagnosing and Treatment of Secondary Progressive Multiple Sclerosis},
journal = {International Journal of Molecular Sciences},
year = {2026},
volume = {27},
number = {10},
pages = {4558},
doi = {10.3390/ijms27104558}
}
EUVIMED